Communicating Research Findings: Changes to FDAMA 114?

With his commentary in the New England Journal of Medicine, Tufts Medical Center Economist Dr. Peter Neumann re-sparked the debate about the type of information that pharmaceutical companies are allowed to share.

We recently sat down with Dr. Neumann to ask him about his commentary. In this video interview, Dr. Neumann explains Section 114 of the Food and Drug Administration Drug Modernization Act of 1997, the law regulating pharmaceutical communications, and how it could be changed to allow a broader exchange of information among health care stakeholders.

Learn more about this issue by reading the Health Affairs articles that contributed to this debate, and view videos and materials from NPC's conference on the topic.